Siteone Therapeutics, Inc.
SiteOne Therapeutics is a clinical-stage biopharmaceutical company focused on developing highly selective small molecule inhibitors targeting sodium channels such as NaV1.7 and NaV1.8 to treat pain, cough, and other hypersensitivity disorders involving the peripheral nervous system. Their mission is to create safe, effective, non-opioid therapeutics for pain and sensory hyperexcitability disorders, with a focus on reducing side effects, abuse potential, and dependence associated with traditional pain treatments.
Industries
Nr. of Employees
small (1-50)
Siteone Therapeutics, Inc.
Bozeman, Montana, United States, North America
Products
Oral NaV1.8 inhibitor (lead clinical candidate)
An orally administered, highly selective small-molecule inhibitor of the NaV1.8 voltage-gated sodium channel in clinical development for acute and chronic peripheral pain; demonstrated safety, tolerability, rapid absorption, and pharmacodynamic evidence of target engagement in Phase 1 studies.
Oral NaV1.8 inhibitor (lead clinical candidate)
An orally administered, highly selective small-molecule inhibitor of the NaV1.8 voltage-gated sodium channel in clinical development for acute and chronic peripheral pain; demonstrated safety, tolerability, rapid absorption, and pharmacodynamic evidence of target engagement in Phase 1 studies.
Services
Discovery and early preclinical development services
Research and lead optimization services for isoform-selective ion channel modulators, including target validation, medicinal chemistry, and preclinical efficacy testing.
Discovery and early preclinical development services
Research and lead optimization services for isoform-selective ion channel modulators, including target validation, medicinal chemistry, and preclinical efficacy testing.
Expertise Areas
- Peripheral nerve-targeted analgesics
- Isoform-selective ion channel drug discovery
- Medicinal chemistry and synthetic scaffold modification
- Preclinical pain pharmacology
Key Technologies
- Isoform-selective voltage-gated sodium channel inhibition
- Small-molecule medicinal chemistry
- Toxin-derived scaffold modification
- Rodent analgesia models